Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1995-06-07
2000-04-04
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
4242321, 4242041, 4242151, 4242171, 424 931, 424 9321, 4242781, 4242771, 4242811, 4352351, 4353201, 530350, 5303871, 536 2372, A61K 3900, C12N 1500
Patent
active
06045802&
ABSTRACT:
The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5126132 (1992-06-01), Rosenberg
patent: 5206353 (1993-04-01), Berger et al.
patent: 5738852 (1998-04-01), Robinson et al.
Kamshaw etal, 1992, TIBTECH, vol. 10, pp. 424-426.
Tartagdia etal, 1990, Immunology, vol. 10, pp. 13-30.
Sivanandham etal, 1994, Cancer Immnol. Immunother., vol. 38, p.259-264.
Tanaka, etal, 1994, J. of Immunotherapy, vol. 16, pp. 283-293.
Lindley, etal, 1994, Gene, vol. 138 pp. 165-170.
J. Ruby et al., 1990, "Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2", Immunol. Cell Biol., 68, 113-117.
Balloul et al, Recombinant Muc 1 Vaccinia Virus: A Potential Vector For Immunotherapy of Breast Cancer, Cellular and Molecular Biology, 40 (Suppl.) I, 49-59, 1994.
Ramsay et al, Enhancement of Mucosal IgA Responses by Interleukins 5 and 6 Encoded in Recombinant Vaccine Vectors, Reprod. Fertil. Dev., 1994, 6, 389-92.
Hellstrom et al, Tumor Immunology: An Overview, Annals of New York Acad. Sci., vol. 690, 1993, pp. 24-31.
Kantor et al, Immunogenicity and Safety of a Recombinant Vaccinia Virus Vaccine Expressing the Carcinoembryonic Antigen Gene in a Nonhuman Primate, Cancer Research, vol. 52, No. 24, 1992, pp. 6917-6925.
Expression of Proteins in Mammalian Cells Using Vaccinia Viral Vectors, Overview of the Vaccinia Virus Expression System, Current Protocols in Molecular Biology, Section IV, Unit 16.15 to 16.19.9, 1991.
Chen et al, Costimulation of Antitumor Immunity by the B7 Counterrecptor For the T Lymphocyte Molecules CD28 and CTLA-4, Cell, vol. 71, 1093-1102, Dec. 24, 1992.
Hellstrom et al, On the Role of Costimulation in Tumor Immunity, Annals of the New York Academy of Sciences, vol. 690, pp. 225-231, Aug. 12, 1993.
Kantor et al, Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine, Journal of the National Cancer Institute, Jul. 15, 1992, vol. 84, No. 14, pp. 1084-1091.
Freeman et al, B7. A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells, The Journal of Immunology, vol. 143, No. 8, Oct. 15, 19889, pp. 2714-2722.
Freeman et al, Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7, J. Exp. Med., vol. 174, Sep. 1991, pp. 625-631.
Freeman et al, Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice, Science, vol. 262, Nov. 5, 1993, pp. 907-909.
Freeman, et al, Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation, Science, vol. 262, Nov. 5, 1993, pp. 909-911.
Schlom, J. et al, Recombinant Vaccines for the Active Specific Immunotherapy of Human Cancer, AIDS Research and Human Retroviruses, vol. 10, Supplement 1, Aug. 1994, Abstract.
Schlom, J. et al, Recombinant Vaccine Strategies for the Immunotherapy of Human Tumors, AIDS Research and Human Retroviruses, vol. 10, Supplement 3, Sep. 1994, Abstract 71.
Hathcock et al, Comparative Analysis of B7-1 and B7-2 Costimulatory Ligands: Expression and Function, The Journal of Experimental Medicine, vol. 180, Aug. 1994, pp. 631-640.
Kaufman et al, A Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen (CEA), Int. J. Cancer, 48, pp. 900-907, 1991.
Current Protocols in Molecular Biology, Generation of Recombinant Vaccinia Viruses, vol. 2 (1994), 16.17.1-16.17.16.
Chen et al, Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-Mediated Tumor Immunity, J. Exp. Med., vol. 179, Feb. 1994, pp 523-532.
Dohring et al, T-Helper- and Accessory-Cell-Independent Cytotoxic Responses to Human Tumor Cells Transfected with a B7 Retroviral Vector, Int. J. Cancer, vol. 57, pp 754-759, 1994.
Li et al, Costimulation of Tumor-Reactive CD4.sup.+ and CD8.sup.+ T Lymphocytes by B7, a Natural Ligand for CD28, Can be Used to Treat Established Mouse Melanoma, The Journal of Immunology, vol. 153, No. 1, Jul. 1, 1994, pp. 421-428.
Bei et al, Enhanced Immune Responses and Anti-Tumor Activity by Baculovirus Recombinant Carcinoembryonic Antigen (CEA) in Mice Primed with the Recombinant Vaccinia CEA, Journal of Immunotherapy, vol. 16, No. 4, 1994, pp. 275-282.
Hodge et al, Induction of Antitumor Immunity by Recombinant Vaccinia Viruses Expressing B7-1 or B7-2 Costimulatory Molecules, Cancer Research, vol. 54, No. 21, Nov. 1, 1994, pp 5552-5555.
Bei et al, Serological and Biochemical Characterization of Recombinant Baculovirus Carcinoembryonic Antigen, Molecular Immunology, vol. 31, No. 10, Jul. 1994, pp. 771-780.
Azuma et al, B7 Antigen is a Second Ligand for CTLA-4 and CD28, Nature, vol. 366, pp. 76-79, Nov. 4, 1993.
Cochran et al, In Vitro Mutagenesis of the Promoter Region for a Vaccinia Virus Gene: Evidence for Tandem Early and Late Regulatory Signals, Journal of Virology, vol. 54, (No. 1) Apr. 1985, pp. 30-37.
Flexner et al, Expression of Human Interleukin-2 by Live Recombinant Vaccinia Virus, Vaccines, 1987, PP, 380-383.
Smith et al, Vaccinia Virus Expression Vectors: Construction Properties and Applications, Biotechniques, Nov./Dec. 1994, pp. 306-312.
Taniguchi et al, Structure and Expression of a Cloned cDNA for Human Interleukin-2, Nature, vol. 302, Mar. 1983, pp. 305-310.
Kawakami et al, Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor, Proc. Natl. Acad. Sci., vol. 91, pp. 3515-3519, Apr. 1994.
Kawakami et al, Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocites Associated with In Vivo Tumor Rejection, Proc. Natl. Acad. Sci., vol. 91, pp. 6458-6462, Jul. 1994.
Kawakami et al, Identification of the Immunodominant Peptides of the Mart-1 Human Melanoma Antigen Recognized by the Majority of HLA-12-Restricted Tumor Infiltrating Lymphocytes, The Journal of Experimental Medicine, vol. 180, Jul. 1994, pp. 347-352.
Rosenberg et al, Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients, Annals of Surgery, vol. 210, No. 4, Oct. 1989, pp. 474-485.
Ochalek et al, In Vitro Generation of Therapeutic Noncytolytic T-Cells by Soluble Polyoma TAA and Il-2, Anticancer Res., 1993 Jul.-Aug., 13(4):1171-7.
Hazama et al, Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein P by Fusion with Biologically Active Interleukin-2, Vaccine 1993; 11(6):629-36.
Hinuma et al, A Novel Strategy for Converting Recombinant Viral Protein into High Immunogenic Antigen, FEBS Letters, 1991, vol. 288, No. 1, 2, pp. 138-142.
Karupiah et al, Recombinant Vaccine Vector-Induced Protection of Athymic, Nude Mice from Influenza A Virus Infection. Analysis of Protective Mechansms, Scan J Immunol 1992 Jul.; 36(1):99-105.
Chen et al, Costimulation of T Cells for Tumor Immurity, Immunology Today, vol. 14, No. 10, 1993, pp. 483-486.
Gaugler et al, Human Gene Mage-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes, J. Exp. Med. vol. 179, Mar. 1994, pp. 921-930.
Freeman et al, B7.1 A New Member of the IG Superfamily with Unique Expression of Activated and Neoplastic B Cells, J. Immunol., vol. 143, 1989, pp. 2714-2722.
Townsend et al, Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells, Science, vol. 259, 1993, pp. 368-370.
Anichina et al, Melanoma Cells and Normal Melanocytes Share Antigens Recognized by HLA-A2-Restricted Cytotoxic T Cells Clones from Melanoma Patients, J. Exp. Med., vol. 177; 1993, pp. 989-998.
Minev et al, Insertion S
Hodge James W.
Kantor Judith
Schlom Jeffrey
Mosher Mary E.
Salimi Ali R.
The United States of America as represented by the Secretary of
LandOfFree
Enhanced immune response to an antigen by a composition of a rec does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced immune response to an antigen by a composition of a rec, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced immune response to an antigen by a composition of a rec will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-362341